Investigational Drug Information for KAF156
✉ Email this page to a colleague
What is the drug development status for KAF156?
KAF156 is an investigational drug.
There have been 8 clinical trials for KAF156.
The most recent clinical trial was a Phase 2 trial, which was initiated on September 11th 2023.
The most common disease conditions in clinical trials are Malaria, Malaria, Falciparum, and Body Weight. The leading clinical trial sponsors are Novartis Pharmaceuticals, Medicines for Malaria Venture, and European and Developing Countries Clinical Trials Partnership (EDCTP).
There are three US patents protecting this investigational drug and forty-five international patents.
Summary for KAF156
| US Patents | 3 |
| International Patents | 45 |
| US Patent Applications | 16 |
| WIPO Patent Applications | 7 |
| Japanese Patent Applications | 1 |
| Clinical Trial Progress | Phase 2 (2023-09-11) |
| Vendors | 38 |
Recent Clinical Trials for KAF156
| Title | Sponsor | Phase |
|---|---|---|
| Efficacy, Safety and Tolerability of KLU156 in Adults and Children ≥ 5 kg Body Weight With Uncomplicated P. Falciparum Malaria | MMV, EDCTP, WANECAM | Phase 3 |
| Efficacy, Safety and Tolerability of KLU156 in Adults and Children ≥ 5 kg Body Weight With Uncomplicated P. Falciparum Malaria | Novartis Pharmaceuticals | Phase 3 |
| Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Efavirenz | Medicines for Malaria Venture | Phase 1 |
Clinical Trial Summary for KAF156
Top disease conditions for KAF156
Top clinical trial sponsors for KAF156
US Patents for KAF156
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| KAF156 | ⤷ Subscribe | Compounds and compositions useful for the treatment of parasitic diseases | IRM LLC (Hamilton, BM) | ⤷ Subscribe |
| KAF156 | ⤷ Subscribe | Compounds and compositions for the treatment of parasitic diseases | Novartis AG (Basel, CH) | ⤷ Subscribe |
| KAF156 | ⤷ Subscribe | Compounds and compositions for the treatment of parasitic disease | Novartis AG (Basel, CH) | ⤷ Subscribe |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for KAF156
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| KAF156 | Argentina | AR077463 | 2029-07-09 | ⤷ Subscribe |
| KAF156 | Australia | AU2010271247 | 2029-07-09 | ⤷ Subscribe |
| KAF156 | Brazil | BR112012000413 | 2029-07-09 | ⤷ Subscribe |
| KAF156 | Canada | CA2767664 | 2029-07-09 | ⤷ Subscribe |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
